Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mabuterol
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Inhalation, Oral
01
Overview
Mabuterol is a long acting, selective β2-adrenoreceptor agonist and bronchodilator used primarily for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). It acts by stimulating β2-adrenoceptors in bronchial smooth muscle, leading to activation of adenylyl cyclase, increased cyclic AMP levels, and subsequent relaxation of airway smooth muscle. This results in bronchodilation and improved airflow. The R-enantiomer is more potent than the S-enantiomer. At higher concentrations, mabuterol may also antagonize beta1 adrenoceptors[4][5][10].
- Brand names
- Broncholin
- Other names
- mabuterolumambuterolMabuterol [INN]Mabuterolum [INN-Latin]MABUTEROL [MI]MABUTEROL [MART.]
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on mabuterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mabuterol.